Evidence map›Paper›PMID 25165466›Full record

ReviewFrontiers in immunology2014

The role of myeloid-derived suppressor cells in immune ontogeny.

Soren Gantt, Ana Gervassi, Heather Jaspan, Helen Horton

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. CCL25 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 4 countries.

Soren GanttChild and Family Research Institute, University of British Columbia , Vancouver, BC , Canada.
Ana GervassiSeattle BioMed , Seattle, WA , USA.
Heather JaspanSeattle BioMed , Seattle, WA , USA ; Division of Immunology, University of Cape Town , Cape Town , South Africa.
Helen HortonSeattle BioMed , Seattle, WA , USA ; Janssen ID&V Research and Development , Antwerp , Belgium.
Center for Infectious Disease Research · USUniversity of British Columbia · CA

Funding

Myeloid-derived Suppressor cells (MDSC) suppress infant immune responsesR01AI100018 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI URDAHL, KEVIN B · 2012 to 2016
$2.2M
Assessing feeding practices, immune activation, and HIV risk in African infantsK08HD069201 · NICHD · SEATTLE CHILDREN'S HOSPITAL · PI JASPAN, HEATHER BERYL · 2011 to 2015
$644k
NIAID NIH HHS R01 AI100018NICHD NIH HHS K08 HD069201
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of granulocytic or monocytic cells that suppress innate as well as adaptive immune responses. In healthy adults, immature myeloid cells differentiate into macrophages, dendritic cells, and granulocytes in the bone marrow and MDSC are rarely detected in peripheral blood. However, in certain pathologies, in particular malignancies and chronic infection, differentiation of these cells is altered resulting in accumulation of circulating suppressive myeloid cells. MDSC express suppressive factors such as arginase-1, reactive oxygen species, and inducible nitric oxide synthase, which have the ability to inhibit T cell proliferation and cytoxicity, induce the expansion of regulatory T cells, and block natural killer cell activation. It is increasingly recognized that MDSC alter the immune response to several cancers, and perhaps chronic viral infections, in clinically important ways. In this review, we outline the potential contribution of MDSC to the generation of feto-maternal tolerance and to the ineffective immune responses to many infections and vaccines observed in early post-natal life. Granulocytic MDSC are present in large numbers in pregnant women and in cord blood, and wane rapidly during infancy. Furthermore, cord blood MDSC suppress in vitro T cell and NK responses, suggesting that they may play a significant role in human immune ontogeny. However, there are currently no data that demonstrate in vivo effects of MDSC on feto-maternal tolerance or immune ontogeny. Studies are ongoing to evaluate the functional importance of MDSC, including their effects on control of infection and response to vaccination in infancy. Importantly, several pharmacologic interventions have the potential to reverse MDSC function. Understanding the role of MDSC in infant ontogeny and their mechanisms of action could lead to interventions that reduce mortality due to early-life infections.

Indexed as

feto-maternal toleranceimmune ontogenymyeloid-derived suppressor cellsneonate

Identifiers

PMID25165466
PMCPMC4131407
OpenAlexW2045878168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.